Stephen B Howell

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Acute Myeloid Leukemia

Top Venues

Bioconjugate chemistry

Molecular cancer therapeutics

The Journal of pharmacology and experimental therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Clara Wong, Maria Carmen Mulero, Erika I Barth, Katherine Wang, Xiying Shang, Sanika Tikle, Catherine Rice, Dennis Gately, Stephen B Howell
Exploiting the receptor-binding domains of RSPO1 to target LGR5-expressing stem cells in ovarian cancer . The Journal of pharmacology and experimental therapeutics (2023)
Himangshu Sonowal, William G Rice, Stephen B Howell
Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. PloS one 18 (3) (2023)
Himangshu Sonowal, William G Rice, Stephen B Howell
Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. PloS one 18 (3) (2023)
Himangshu Sonowal, William G Rice, Stephen B Howell
Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. PloS one 18 (3) (2023)
William G Rice, Stephen B Howell, Hongying Zhang, Nasrin Rastgoo, Andrea Local, Stephen E Kurtz, Pierrette Lo, Daniel Bottomly, Beth Wilmot, Shannon K McWeeney, Brian J Druker, Jeffrey W Tyner
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia. Molecular cancer therapeutics 21 (7) (2022)
Songman Yu, Maria Carmen Mulero, Wannan Chen, Xiying Shang, Songyu Tian, Joji Watanabe, Arisa Watanabe, Tim Vorberg, Clara Wong, Dennis Gately, Stephen B Howell
Therapeutic Targeting of Tumor Cells Rich in LGR Stem Cell Receptors. Bioconjugate chemistry 32 (2) (2021)